Forte's Q2 Loss Widens to $23.3M as FB102 R&D Spend Surges 162%

summarizeSummary

Forte Biosciences reported a wider Q2 net loss of $23.3 million as R&D spending on FB102 surged 162% year-over-year. The company has $198.5 million in cash and remains on track for its pending $77-per-share acquisition by argenx.

check_boxKey Events · Earnings and Guidance · FBRX

• Q2 Net Loss Widens to $23.3M

  Net loss for the three months ended June 30, 2026 was $23.3 million, up from $11.2 million in Q2 2025, driven by a 162% increase in R&D expenses to $22.3 million.

• R&D Spend Surges on FB102 Trials

  Research and development expenses rose to $22.3 million for the quarter, primarily due to manufacturing and clinical costs for the Phase 2 celiac trial and Phase 1b vitiligo and alopecia areata trials.

• Cash Runway Exceeds 12 Months

  Cash, cash equivalents and short-term investments totaled $198.5 million as of June 30, 2026, which management believes is sufficient to fund operations for at least twelve months.

• Insurance Settlement Proceeds Boost G&A

  General and administrative expenses decreased to $2.3 million from $3.0 million, reflecting $2.5 million received from Wesco Insurance in Q2 as part of a $4.8 million total settlement during the six months.

auto_awesomeAnalysis · FBRX · Life Sciences

Forte's Q2 results show a sharp increase in R&D spending as it advances FB102 through multiple clinical trials, with the net loss widening to $23.3 million from $11.2 million a year ago. The company holds $198.5 million in cash and investments, enough for at least 12 months, but the pending $77-per-share acquisition by argenx remains the dominant factor for shareholders. The financials provide a snapshot of the company's standalone trajectory, but the merger's closing conditions and tender offer progress will ultimately determine the stock's fate.